2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
3
Unknown
1
Completed
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
1
Conditions
Tourette Syndrome
1
Stress Disorders, Post-Traumatic
1
Sleep Initiation and Maintenance Disorders
1
Severe Acute Respiratory Syndrome
1
Seizures
1
Parkinson Disease
1
Opioid-Related Disorders
1
Neoplasms
1
Multiple Sclerosis
1
Inflammatory Bowel Diseases
1
Hepatitis C
1
Glaucoma
1
Fibromyalgia
1
Epilepsy
1
Depression
1
Crohn Disease
1
Coronavirus Infections
1
Colitis, Ulcerative
1
Chronic Traumatic Encephalopathy
1
Chronic Pain
1
COVID-19
1
Brain Injuries, Traumatic
1
Bipolar Disorder
1
Autistic Disorder
1
Anxiety Disorders
1
Anemia, Sickle Cell
1
Amyotrophic Lateral Sclerosis
1
Acquired Immunodeficiency Syndrome
1
Interventions
Cisplatin
517
Radiotherapy
378
Cyclophosphamide
368
Carboplatin
359
Capecitabine
342
Paclitaxel
337
Oxaliplatin
336
Gemcitabine
322
Docetaxel
317
Fluorouracil
290
Drug Therapy
276
Bevacizumab
248
apatinib
247
camrelizumab
219
Etoposide
201
Irinotecan
182
Doxorubicin
181
Leucovorin
163
Dexamethasone
161
pembrolizumab
153
Neoadjuvant Therapy
146
sintilimab
145
anlotinib
140
Blood Specimen Collection
140
Pemetrexed
138
Cytarabine
138
toripalimab
133
Surgical Procedures, Operative
131
Radiosurgery
131
S 1 (combination)
125
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Medical Marijuana
×
Clear all
NCT03944447
2022-06-02
OMNI-Can
OMNI Medical Services, LLC
Phase 2
Unknown
200,000 enrolled